Oruka Therapeutics, Inc.
NGM: ORKALive Quote
📈 ZcoreAI Score
Our AI model analyzes Oruka Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ORKA Z-Score →About Oruka Therapeutics, Inc.
Healthcare
Biotechnology
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
📊 Fundamental Analysis
Oruka Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -24.7%, which indicates that capital utilization is currently under pressure.
At a current price of $59.58, ORKA currently trades near the top of its 52-week range (91%) (Range: $7.62 - $64.61).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
Key Financials
Market Cap
$2.95B
Trailing P/E
--
Forward P/E
-23.46
Beta (5Y)
--
52W High
$64.61
52W Low
$7.62
Avg Volume
634K
Day High
Day Low